Skip to main page content
Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

My NCBI Filters
Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1986 1
1988 1
1991 1
1992 2
1993 1
1994 1
1995 2
1996 1
1997 1
1999 1
2000 1
2003 2
2007 1
2011 1
2016 1
2021 1
Text availability
Article attribute
Article type
Publication date

Search Results

19 results
Results by year
Filters applied: . Clear all
Page 1
Mitoxantrone and hepatic toxicity.
Paciucci PA, Sklarin NT. Paciucci PA, et al. Among authors: sklarin nt. Ann Intern Med. 1986 Nov;105(5):805-6. doi: 10.7326/0003-4819-105-5-805_3. Ann Intern Med. 1986. PMID: 3767174 No abstract available.
Bevacizumab 5 mg/kg can be infused safely over 10 minutes.
Reidy DL, Chung KY, Timoney JP, Park VJ, Hollywood E, Sklarin NT, Muller RJ, Saltz LB. Reidy DL, et al. Among authors: sklarin nt. J Clin Oncol. 2007 Jul 1;25(19):2691-5. doi: 10.1200/JCO.2006.09.3351. J Clin Oncol. 2007. PMID: 17602073
A Phase I Study of Alpelisib in Combination with Trastuzumab and LJM716 in Patients with PIK3CA-Mutated HER2-Positive Metastatic Breast Cancer.
Jhaveri K, Drago JZ, Shah PD, Wang R, Pareja F, Ratzon F, Iasonos A, Patil S, Rosen N, Fornier MN, Sklarin NT, Chandarlapaty S, Modi S. Jhaveri K, et al. Among authors: sklarin nt. Clin Cancer Res. 2021 Jul 15;27(14):3867-3875. doi: 10.1158/1078-0432.CCR-21-0047. Epub 2021 May 4. Clin Cancer Res. 2021. PMID: 33947692
19 results
You have reached the last page of results. A maximum of 10,000 results are available.
Jump to page